🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with figures suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in the same week. This drug, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on results published in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The study included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Doctors treating patients have voiced optimism. Having a one-pill regimen like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.